PD L1 News and Research

RSS

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018

Cancer cells release biological 'drones' to assist in the fight against immune system

Cancer cells are more than a lump of cells growing out of control; they participate in active combat with the immune system for their own survival. Being able to evade the immune system is a hallmark of cancer.

9 Aug 2018

Blood-based test accurately identifies lung cancer patients who could benefit from immunotherapies

Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.

7 Aug 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

19 Jul 2018

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

12 Jul 2018

Study uncovers process that neutralizes tumor cells

Researchers from the University of California San Diego have identified an unexpected mechanism that could help determine whether a cancer patient will respond to immunotherapy.

11 Jul 2018

Researchers find new marker for better prognosis in gastric and esophageal cancer

Tumors that develop at the transition of the stomach to the esophagus, so-called adenocarcinomas of the gastroesophageal transition, are still difficult to treat and the chances of recovery are still low.

2 Jul 2018

Research shows why new cancer therapies fail to work on some patients

University of Otago research provides insights into an underlying mechanism that could explain why new cancer therapies to help treat metastatic melanoma do not always work on patients, paving the way for predicting which patients will benefit from certain drugs.

30 Jun 2018

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

4 May 2018

New study evaluates expression of PD-L1 in human medulloblastoma

This study evaluated the expression of PD-L1 and markers of immune mediated resistance in human medulloblastoma, the most common malignant pediatric brain tumor.

3 May 2018

New vaccine strategy increases number of tumor-specific cancer-killing T cells

New research published in Cancer Immunology Research by Drs. Esteban Celis and Hussein Sultan of the Georgia Cancer Center at Augusta University could serve as the stepping-stone in constructing vaccines with a greater likelihood of finding and attacking tumors in the human body.

2 May 2018

Researchers discover new information related to rare form of leukemia

International research consortium led by researchers from the University of Helsinki, Finland, discovered new information related to a rare form of leukemia called aggressive NK-cell leukemia.

20 Apr 2018

Precancerous colon polyps in Lynch syndrome patients display immune activation

Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation well before cancer development, according to research from The University of Texas MD Anderson Cancer Center.

16 Apr 2018

Study provides systematic view of gene enhancer activity in diverse tumors

At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian nesting-doll of gene regulatory layers, within those increasingly smaller tiers are short pieces of non-coding DNA called enhancers.

5 Apr 2018

Researchers unravel immunopathogenesis of Johne's disease

A research team has unraveled the immunopathogenesis of Johne's disease, a chronic bovine disease that has caused endemics in Japan and many other countries, placing financial burdens on cattle farmers.

2 Apr 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

Johns Hopkins researchers invent new class of immunotherapy drugs to fight cancer

Johns Hopkins researchers have invented a new class of cancer immunotherapy drugs that are more effective at harnessing the power of the immune system to fight cancer.

2 Mar 2018

Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism

Novel bifunctional immunotherapeutic agents have been developed that, as well as deactivating key immune checkpoints,deactivate the tumor's protective response.

23 Feb 2018